Table 2.
An overview of various clinical trials examining CAR-Ts against various target antigens for the treatment of solid tumours, including TNBC
| Target antigen | ClinicalTrials.gov identifier | Phase | Participants | Source | Start-completion date |
|---|---|---|---|---|---|
| NKG2D ligand | NCT04107142 | I | 10 | Allogeneic | 2019–2021 |
| ROR1 | NCT02706392 | I | 21 | Allogeneic | 2016–2021 |
| c-Met |
I Early I |
6 | Allogeneic |
2013–2018 2016–2020 |
|
| Mesothelin |
I I I I/II |
77 18 20 186 113 |
Allogeneic |
2011–2015 2015–2018 2016–2023 2015–2024 |
|
| MUC1 | NCT02587689 | I/II | 20 | Allogeneic | 2015–2018 |
| A cleaved form of MUC1 | NCT04020575 | I | 69 | Allogeneic | 2020–2035 |
| TnMUC1 | NCT04025216 | I | 112 | Allogeneic | 2019–2036 |